Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of vosoritide (Voxzogo) in children with achondroplasia
2023-508864-31-00Phase 3Authorised
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Primary endpoints: Change from baseline in annualized growth velocity (AGV), Change from baseline in height Z-score and 9 more. Planned start Apr 2024; status: authorised.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2023-508864-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508864-31-00.